Pharma Sector Growth: Skills, Innovation Key - Economic Survey
Jul 22, 2024 13:39
India's pharma sector, valued at USD 50 billion, is projected to reach USD 130 billion by 2030. Economic Survey highlights the need for skill development, innovation, and a robust supply chain for continued growth.
New Delhi, Jul 22 (PTI) The domestic pharmaceutical industry needs skill advancement, innovation and a strong supply chain with the segment size expected to touch USD 130 billion by 2030, said Economic Survey 2023-24 tabled in Parliament on Monday.
The Indian pharmaceutical market is currently valued at around USD 50 billion and is the world's third-largest by volume.
"Pharma industry is expected to reach USD 130 billion by 2030. The next leg of growth in pharma necessitates skill advancement, the use of innovation and technology, and the establishment of a strong supply chain," the survey said.
India's strength in the pharmaceutical sector lies in being a cost effective and efficient producer of existing off-patent drugs -- also called the generic industry, it stated.
The world needs both the innovators and those that can provide drugs at a reasonable price, with the latter playing a vital role in enhancing social benefits.
The development of new drugs aimed at addressing unaddressed health concerns will improve the breadth and quality of healthcare access for the population, while producing better returns on investments, it stated.
"Hence, the strength of the industry lies in having a diverse combination of innovators and generic producers. As we move towards realising the vision of Viksit Bharat, it is vital to promote innovation," the survey added.
The Economic Survey 2023-24 also noted that the export growth in the sector can be sustained by increasing the capabilities in biopharmaceuticals manufacturing.
The export has witnessed growth in the last 5-6 decades due to consistent innovation, the survey stated.
It noted that India is largely dependent on imports for many antibiotic Active Pharmaceutical Ingredients (APIs) manufactured through fermentation.
"India's import dependency is largely due to a lack of cost-effective options in domestic API manufacturing compared to imports," the survey opined.
Domestic infrastructure and R&D capabilities have improved considerably in recent years, but challenges remain, it added.
Home »
Market News » Pharma Sector Growth: Skills, Innovation Key - Economic Survey
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
MORE NEWS
Coal India Aims for Dividend Return by FY'26
Coal India aims to eliminate ECL's losses and rejoin the dividend list by FY'26, with...
Gold Poised for 15-18% Returns in Samvat 2081:...
Analysts predict a strong 15-18% return for gold in Samvat 2081, driven by positive...
Punjab Paddy Procurement Crosses 85 Lakh...
Punjab has procured 85.41 lakh tonnes of paddy in the 2024-25 kharif marketing season,...
Microsoft Sees No Tech Spend Slowdown in India,...
Microsoft India President Puneet Chandok highlights strong tech spending in India,...
Business School Applications Surge Despite...
Applications for business school graduate programmes soared 12% in 2024, driven by...
Sebi Fines Sunil Lulla Rs 50 Lakh for Market...
Sebi has imposed a Rs 50 lakh fine on Sunil Lulla, former MD of Eros International, for...
Anarock Revenue to Rise 40% to Rs 800 Cr: Anuj...
Anarock Group forecasts a 40% revenue increase to Rs 800 crore in FY25 driven by strong...
Magicpin Cuts Delivery Fee to Rs 5: Zomato,...
Magicpin slashes its platform fee to Rs 5 per delivery, while Zomato and Swiggy raise...
Dr Reddy's Recalls Cinacalcet Tablets in US: USFDA
Dr Reddy's Laboratories is recalling over 3.3 lakh bottles of Cinacalcet tablets in the...
Tamil Nadu: Distributed Growth, Tier 2 Cities,...
Tamil Nadu is focusing on distributed growth, boosting industrial development in tier 2...
Read More »